A panel of outside advisers to the U.S. Food and Drug Administration overwhelmingly endorsed emergency use of Moderna Inc.’s coronavirus vaccine, virtually assuring a second option for protecting against Covid-19 for a pandemic-ravaged nation.

An AstraZeneca executive said he felt encouraged by “incredibly promising” large-scale Covid-19 vaccine trial results unveiled by New York-based Pfizer and the company’s German partner BioNTech.

Moderna Inc. Chief Executive Officer Stéphane Bancel expects interim results from the company’s Covid-19 vaccine trial in November and that the U.S government could give an emergency use nod in December, the Wall Street Journal reported.

Moderna Inc. will not be ready to apply for emergency authorization for the potential Covid-19 vaccine mRNA-1273 before the U.S. presidential election in November, the Financial Times reported, citing the company’s chief executive officer.

Britain will host clinical trials where volunteers are deliberately infected with the new coronavirus to test the effectiveness of vaccine candidates, the Financial Times reported, citing people involved in the project.

Although it’s increasingly likely that one of the Covid-19 vaccines being tested will be approved or receive Emergency Use Authorization (EUA) before the end of 2020, experts are increasingly warning that widespread distribution may take a much longer time.

Former U.S. Food and Drug Administration Commissioner Scott Gottlieb criticized current FDA Commissioner Stephen Hahn’s comments to the Financial Times that he would potentially fast-track a Covid-19 vaccine before clinical trials are done if it was “appropriate.”

The head of the U.S. Food and Drug Administration is willing to fast-track a Covid-19 vaccine as quickly as possible, the Financial Times reported him as saying in a published interview.

British drugmaker AstraZeneca started testing an antibody-based cocktail for the prevention and treatment of Covid-19, adding to recent signs of progress on possible medical solutions to the disease caused by the novel coronavirus.

Moderna Inc. is planning to price the company’s coronavirus vaccine at $50 to $60 per course — higher than other vaccine makers have agreed to charge governments, the Financial Times reported.